nodes	percent_of_prediction	percent_of_DWPC	metapath
Ethosuximide—CYP3A5—Teniposide—lymphatic system cancer	0.171	0.204	CbGbCtD
Ethosuximide—CYP2E1—Mitoxantrone—lymphatic system cancer	0.154	0.183	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.11	0.131	CbGbCtD
Ethosuximide—CYP3A7—Vincristine—lymphatic system cancer	0.11	0.131	CbGbCtD
Ethosuximide—CYP3A5—Vincristine—lymphatic system cancer	0.0824	0.098	CbGbCtD
Ethosuximide—CYP3A4—Cytarabine—lymphatic system cancer	0.0678	0.0806	CbGbCtD
Ethosuximide—CYP3A4—Teniposide—lymphatic system cancer	0.0667	0.0794	CbGbCtD
Ethosuximide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0467	0.0555	CbGbCtD
Ethosuximide—CYP3A4—Vincristine—lymphatic system cancer	0.0321	0.0382	CbGbCtD
Ethosuximide—Paranoia—Carmustine—lymphatic system cancer	0.0032	0.0201	CcSEcCtD
Ethosuximide—Pancytopenia—Mechlorethamine—lymphatic system cancer	0.00313	0.0196	CcSEcCtD
Ethosuximide—Sleep disorder—Fludarabine—lymphatic system cancer	0.00286	0.0179	CcSEcCtD
Ethosuximide—Aggression—Bleomycin—lymphatic system cancer	0.00284	0.0178	CcSEcCtD
Ethosuximide—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.00274	0.0172	CcSEcCtD
Ethosuximide—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0025	0.0157	CcSEcCtD
Ethosuximide—Pancytopenia—Teniposide—lymphatic system cancer	0.00231	0.0145	CcSEcCtD
Ethosuximide—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00206	0.0129	CcSEcCtD
Ethosuximide—Pancytopenia—Fludarabine—lymphatic system cancer	0.00203	0.0127	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00194	0.0122	CcSEcCtD
Ethosuximide—Mental disability—Carmustine—lymphatic system cancer	0.00189	0.0119	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00189	0.0118	CcSEcCtD
Ethosuximide—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00182	0.0114	CcSEcCtD
Ethosuximide—Haematuria—Fludarabine—lymphatic system cancer	0.00182	0.0114	CcSEcCtD
Ethosuximide—Anorexia—Mechlorethamine—lymphatic system cancer	0.00179	0.0112	CcSEcCtD
Ethosuximide—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00163	0.0102	CcSEcCtD
Ethosuximide—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00162	0.0101	CcSEcCtD
Ethosuximide—Agitation—Teniposide—lymphatic system cancer	0.00156	0.00976	CcSEcCtD
Ethosuximide—Leukopenia—Teniposide—lymphatic system cancer	0.00152	0.00951	CcSEcCtD
Ethosuximide—Malnutrition—Fludarabine—lymphatic system cancer	0.00149	0.00934	CcSEcCtD
Ethosuximide—Pancytopenia—Bleomycin—lymphatic system cancer	0.00149	0.00933	CcSEcCtD
Ethosuximide—Ataxia—Carmustine—lymphatic system cancer	0.00149	0.00933	CcSEcCtD
Ethosuximide—Ataxia—Vincristine—lymphatic system cancer	0.00142	0.00891	CcSEcCtD
Ethosuximide—Weight decreased—Bleomycin—lymphatic system cancer	0.00142	0.00889	CcSEcCtD
Ethosuximide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00138	0.00867	CcSEcCtD
Ethosuximide—Agitation—Fludarabine—lymphatic system cancer	0.00137	0.00858	CcSEcCtD
Ethosuximide—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00134	0.00843	CcSEcCtD
Ethosuximide—Leukopenia—Fludarabine—lymphatic system cancer	0.00133	0.00836	CcSEcCtD
Ethosuximide—Haematuria—Bleomycin—lymphatic system cancer	0.00133	0.00835	CcSEcCtD
Ethosuximide—Anorexia—Teniposide—lymphatic system cancer	0.00132	0.00827	CcSEcCtD
Ethosuximide—Pancytopenia—Carmustine—lymphatic system cancer	0.0013	0.00815	CcSEcCtD
Ethosuximide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00128	0.00805	CcSEcCtD
Ethosuximide—Pancytopenia—Vincristine—lymphatic system cancer	0.00124	0.00778	CcSEcCtD
Ethosuximide—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00121	0.00757	CcSEcCtD
Ethosuximide—Decreased appetite—Teniposide—lymphatic system cancer	0.0012	0.00754	CcSEcCtD
Ethosuximide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00119	0.00748	CcSEcCtD
Ethosuximide—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00119	0.00747	CcSEcCtD
Ethosuximide—Rash—Mechlorethamine—lymphatic system cancer	0.00118	0.00742	CcSEcCtD
Ethosuximide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00118	0.00741	CcSEcCtD
Ethosuximide—Weight decreased—Vincristine—lymphatic system cancer	0.00118	0.00741	CcSEcCtD
Ethosuximide—Anorexia—Fludarabine—lymphatic system cancer	0.00116	0.00726	CcSEcCtD
Ethosuximide—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00115	0.00721	CcSEcCtD
Ethosuximide—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00113	0.00711	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00113	0.00709	CcSEcCtD
Ethosuximide—Nausea—Mechlorethamine—lymphatic system cancer	0.00111	0.00699	CcSEcCtD
Ethosuximide—Urticaria—Teniposide—lymphatic system cancer	0.0011	0.00689	CcSEcCtD
Ethosuximide—Abdominal pain—Teniposide—lymphatic system cancer	0.00109	0.00686	CcSEcCtD
Ethosuximide—Haematuria—Mitoxantrone—lymphatic system cancer	0.00108	0.00678	CcSEcCtD
Ethosuximide—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00108	0.00675	CcSEcCtD
Ethosuximide—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00106	0.00664	CcSEcCtD
Ethosuximide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00106	0.00663	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00105	0.00658	CcSEcCtD
Ethosuximide—Fatigue—Fludarabine—lymphatic system cancer	0.00105	0.00657	CcSEcCtD
Ethosuximide—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00103	0.00647	CcSEcCtD
Ethosuximide—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00103	0.00644	CcSEcCtD
Ethosuximide—Urethral disorder—Vincristine—lymphatic system cancer	0.00102	0.00642	CcSEcCtD
Ethosuximide—Eye disorder—Carmustine—lymphatic system cancer	0.00102	0.00642	CcSEcCtD
Ethosuximide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00102	0.00639	CcSEcCtD
Ethosuximide—Asthenia—Teniposide—lymphatic system cancer	0.000992	0.00622	CcSEcCtD
Ethosuximide—Leukopenia—Bleomycin—lymphatic system cancer	0.000977	0.00613	CcSEcCtD
Ethosuximide—Mental disorder—Carmustine—lymphatic system cancer	0.000959	0.00601	CcSEcCtD
Ethosuximide—Malnutrition—Carmustine—lymphatic system cancer	0.000953	0.00598	CcSEcCtD
Ethosuximide—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.000948	0.00595	CcSEcCtD
Ethosuximide—Diarrhoea—Teniposide—lymphatic system cancer	0.000946	0.00593	CcSEcCtD
Ethosuximide—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000942	0.00591	CcSEcCtD
Ethosuximide—Mental disorder—Vincristine—lymphatic system cancer	0.000915	0.00574	CcSEcCtD
Ethosuximide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000895	0.00562	CcSEcCtD
Ethosuximide—Vomiting—Teniposide—lymphatic system cancer	0.000879	0.00551	CcSEcCtD
Ethosuximide—Agitation—Carmustine—lymphatic system cancer	0.000876	0.00549	CcSEcCtD
Ethosuximide—Asthenia—Fludarabine—lymphatic system cancer	0.000872	0.00547	CcSEcCtD
Ethosuximide—Rash—Teniposide—lymphatic system cancer	0.000872	0.00547	CcSEcCtD
Ethosuximide—Dermatitis—Teniposide—lymphatic system cancer	0.000871	0.00546	CcSEcCtD
Ethosuximide—Headache—Teniposide—lymphatic system cancer	0.000866	0.00543	CcSEcCtD
Ethosuximide—Leukopenia—Carmustine—lymphatic system cancer	0.000853	0.00535	CcSEcCtD
Ethosuximide—Anorexia—Bleomycin—lymphatic system cancer	0.000849	0.00533	CcSEcCtD
Ethosuximide—Agitation—Vincristine—lymphatic system cancer	0.000836	0.00524	CcSEcCtD
Ethosuximide—Diarrhoea—Fludarabine—lymphatic system cancer	0.000831	0.00521	CcSEcCtD
Ethosuximide—Nausea—Teniposide—lymphatic system cancer	0.000821	0.00515	CcSEcCtD
Ethosuximide—Leukopenia—Vincristine—lymphatic system cancer	0.000814	0.00511	CcSEcCtD
Ethosuximide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000793	0.00497	CcSEcCtD
Ethosuximide—Decreased appetite—Bleomycin—lymphatic system cancer	0.000774	0.00486	CcSEcCtD
Ethosuximide—Vomiting—Fludarabine—lymphatic system cancer	0.000773	0.00485	CcSEcCtD
Ethosuximide—Rash—Fludarabine—lymphatic system cancer	0.000766	0.00481	CcSEcCtD
Ethosuximide—Dermatitis—Fludarabine—lymphatic system cancer	0.000765	0.0048	CcSEcCtD
Ethosuximide—Headache—Fludarabine—lymphatic system cancer	0.000761	0.00477	CcSEcCtD
Ethosuximide—Lethargy—Methotrexate—lymphatic system cancer	0.000748	0.00469	CcSEcCtD
Ethosuximide—Anorexia—Carmustine—lymphatic system cancer	0.000741	0.00465	CcSEcCtD
Ethosuximide—Nervous system disorder—Vincristine—lymphatic system cancer	0.000728	0.00457	CcSEcCtD
Ethosuximide—Nausea—Fludarabine—lymphatic system cancer	0.000722	0.00453	CcSEcCtD
Ethosuximide—Urticaria—Bleomycin—lymphatic system cancer	0.000708	0.00444	CcSEcCtD
Ethosuximide—Anorexia—Vincristine—lymphatic system cancer	0.000708	0.00444	CcSEcCtD
Ethosuximide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000702	0.0044	CcSEcCtD
Ethosuximide—Irritability—Methotrexate—lymphatic system cancer	0.000699	0.00439	CcSEcCtD
Ethosuximide—Somnolence—Carmustine—lymphatic system cancer	0.000691	0.00434	CcSEcCtD
Ethosuximide—Anorexia—Mitoxantrone—lymphatic system cancer	0.000689	0.00432	CcSEcCtD
Ethosuximide—Ataxia—Methotrexate—lymphatic system cancer	0.000689	0.00432	CcSEcCtD
Ethosuximide—Decreased appetite—Carmustine—lymphatic system cancer	0.000676	0.00424	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000671	0.00421	CcSEcCtD
Ethosuximide—Breast disorder—Methotrexate—lymphatic system cancer	0.000662	0.00415	CcSEcCtD
Ethosuximide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000656	0.00412	CcSEcCtD
Ethosuximide—Decreased appetite—Vincristine—lymphatic system cancer	0.000645	0.00405	CcSEcCtD
Ethosuximide—Somnolence—Mitoxantrone—lymphatic system cancer	0.000643	0.00403	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000641	0.00402	CcSEcCtD
Ethosuximide—Fatigue—Vincristine—lymphatic system cancer	0.00064	0.00401	CcSEcCtD
Ethosuximide—Asthenia—Bleomycin—lymphatic system cancer	0.000639	0.00401	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000636	0.00399	CcSEcCtD
Ethosuximide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000628	0.00394	CcSEcCtD
Ethosuximide—Eosinophilia—Methotrexate—lymphatic system cancer	0.000627	0.00393	CcSEcCtD
Ethosuximide—Fatigue—Mitoxantrone—lymphatic system cancer	0.000623	0.00391	CcSEcCtD
Ethosuximide—Abdominal pain—Carmustine—lymphatic system cancer	0.000615	0.00386	CcSEcCtD
Ethosuximide—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000607	0.00381	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000607	0.00381	CcSEcCtD
Ethosuximide—Pancytopenia—Methotrexate—lymphatic system cancer	0.000602	0.00377	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000591	0.00371	CcSEcCtD
Ethosuximide—Abdominal pain—Vincristine—lymphatic system cancer	0.000587	0.00368	CcSEcCtD
Ethosuximide—Urticaria—Mitoxantrone—lymphatic system cancer	0.000574	0.0036	CcSEcCtD
Ethosuximide—Hypersensitivity—Carmustine—lymphatic system cancer	0.000573	0.00359	CcSEcCtD
Ethosuximide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000571	0.00358	CcSEcCtD
Ethosuximide—Vomiting—Bleomycin—lymphatic system cancer	0.000566	0.00355	CcSEcCtD
Ethosuximide—Drowsiness—Methotrexate—lymphatic system cancer	0.000565	0.00354	CcSEcCtD
Ethosuximide—Rash—Bleomycin—lymphatic system cancer	0.000562	0.00352	CcSEcCtD
Ethosuximide—Dermatitis—Bleomycin—lymphatic system cancer	0.000561	0.00352	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00056	0.00351	CcSEcCtD
Ethosuximide—Asthenia—Carmustine—lymphatic system cancer	0.000558	0.0035	CcSEcCtD
Ethosuximide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000547	0.00343	CcSEcCtD
Ethosuximide—Haematuria—Methotrexate—lymphatic system cancer	0.000538	0.00338	CcSEcCtD
Ethosuximide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000533	0.00334	CcSEcCtD
Ethosuximide—Asthenia—Vincristine—lymphatic system cancer	0.000533	0.00334	CcSEcCtD
Ethosuximide—Diarrhoea—Carmustine—lymphatic system cancer	0.000532	0.00334	CcSEcCtD
Ethosuximide—Nausea—Bleomycin—lymphatic system cancer	0.000529	0.00332	CcSEcCtD
Ethosuximide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000527	0.00331	CcSEcCtD
Ethosuximide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000519	0.00325	CcSEcCtD
Ethosuximide—Dizziness—Carmustine—lymphatic system cancer	0.000514	0.00323	CcSEcCtD
Ethosuximide—Diarrhoea—Vincristine—lymphatic system cancer	0.000508	0.00319	CcSEcCtD
Ethosuximide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000501	0.00314	CcSEcCtD
Ethosuximide—Urethral disorder—Methotrexate—lymphatic system cancer	0.000497	0.00312	CcSEcCtD
Ethosuximide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000495	0.0031	CcSEcCtD
Ethosuximide—Vomiting—Carmustine—lymphatic system cancer	0.000494	0.0031	CcSEcCtD
Ethosuximide—Dizziness—Vincristine—lymphatic system cancer	0.000491	0.00308	CcSEcCtD
Ethosuximide—Rash—Carmustine—lymphatic system cancer	0.00049	0.00308	CcSEcCtD
Ethosuximide—Dermatitis—Carmustine—lymphatic system cancer	0.00049	0.00307	CcSEcCtD
Ethosuximide—Headache—Carmustine—lymphatic system cancer	0.000487	0.00306	CcSEcCtD
Ethosuximide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000479	0.00301	CcSEcCtD
Ethosuximide—Eye disorder—Methotrexate—lymphatic system cancer	0.000474	0.00297	CcSEcCtD
Ethosuximide—Vomiting—Vincristine—lymphatic system cancer	0.000472	0.00296	CcSEcCtD
Ethosuximide—Rash—Vincristine—lymphatic system cancer	0.000468	0.00294	CcSEcCtD
Ethosuximide—Dermatitis—Vincristine—lymphatic system cancer	0.000468	0.00293	CcSEcCtD
Ethosuximide—Headache—Vincristine—lymphatic system cancer	0.000465	0.00292	CcSEcCtD
Ethosuximide—Nausea—Carmustine—lymphatic system cancer	0.000462	0.0029	CcSEcCtD
Ethosuximide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00046	0.00288	CcSEcCtD
Ethosuximide—Immune system disorder—Methotrexate—lymphatic system cancer	0.000458	0.00287	CcSEcCtD
Ethosuximide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000457	0.00287	CcSEcCtD
Ethosuximide—Rash—Mitoxantrone—lymphatic system cancer	0.000456	0.00286	CcSEcCtD
Ethosuximide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000455	0.00286	CcSEcCtD
Ethosuximide—Headache—Mitoxantrone—lymphatic system cancer	0.000453	0.00284	CcSEcCtD
Ethosuximide—Mental disorder—Methotrexate—lymphatic system cancer	0.000444	0.00279	CcSEcCtD
Ethosuximide—Malnutrition—Methotrexate—lymphatic system cancer	0.000441	0.00277	CcSEcCtD
Ethosuximide—Nausea—Vincristine—lymphatic system cancer	0.000441	0.00277	CcSEcCtD
Ethosuximide—Nausea—Mitoxantrone—lymphatic system cancer	0.000429	0.00269	CcSEcCtD
Ethosuximide—Leukopenia—Methotrexate—lymphatic system cancer	0.000395	0.00248	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000373	0.00234	CcSEcCtD
Ethosuximide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000353	0.00222	CcSEcCtD
Ethosuximide—Skin disorder—Methotrexate—lymphatic system cancer	0.00035	0.00219	CcSEcCtD
Ethosuximide—Anorexia—Methotrexate—lymphatic system cancer	0.000343	0.00215	CcSEcCtD
Ethosuximide—Somnolence—Methotrexate—lymphatic system cancer	0.00032	0.00201	CcSEcCtD
Ethosuximide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000313	0.00196	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000311	0.00195	CcSEcCtD
Ethosuximide—Fatigue—Methotrexate—lymphatic system cancer	0.000311	0.00195	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000295	0.00185	CcSEcCtD
Ethosuximide—Urticaria—Methotrexate—lymphatic system cancer	0.000286	0.00179	CcSEcCtD
Ethosuximide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000285	0.00179	CcSEcCtD
Ethosuximide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000265	0.00166	CcSEcCtD
Ethosuximide—Asthenia—Methotrexate—lymphatic system cancer	0.000258	0.00162	CcSEcCtD
Ethosuximide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000246	0.00155	CcSEcCtD
Ethosuximide—Dizziness—Methotrexate—lymphatic system cancer	0.000238	0.00149	CcSEcCtD
Ethosuximide—Vomiting—Methotrexate—lymphatic system cancer	0.000229	0.00144	CcSEcCtD
Ethosuximide—Rash—Methotrexate—lymphatic system cancer	0.000227	0.00142	CcSEcCtD
Ethosuximide—Dermatitis—Methotrexate—lymphatic system cancer	0.000227	0.00142	CcSEcCtD
Ethosuximide—Headache—Methotrexate—lymphatic system cancer	0.000226	0.00142	CcSEcCtD
Ethosuximide—Nausea—Methotrexate—lymphatic system cancer	0.000214	0.00134	CcSEcCtD
